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Abstract
Stoke is a leading cause of disability and mortality across the globe, making it a global health
crisis. However, treatments for stroke remain limited with narrow therapeutic time window.
Visual impairment negatively affects patients’ quality of life. During stroke, the disruption in
blood flow might affect both brain and eye resulting in cerebral and retinal ischemia. Currently,
there is a lack of treatment option that targets both cerebral and retinal ischemia. Ischemic stroke
pathology is complex and multiphasic. The ischemic event is followed by a secondary cascade of
inflammatory cytokines exacerbating the initial focal injury and expanding into the penumbra. In
recent years, mitochondrial dysfunction has been identified as a hallmark pathological of
ischemia and reperfusion injuries. This pathology is marked by an increase in oxidative stress
and reduced oxidative phosphorylation. Investigations have begun to shine the spotlight on
mitochondrial dysfunction as the key contributor in stroke pathology. The role of stem cells as a
therapeutic option has been growing over the last decade, particularly in central nervous system
disorders. However, the underlying therapeutic mechanisms of stem cell therapy remain elusive.
In the present work, we investigated the role of mitochondrial dysfunction as a key mechanism
of cell death in stroke-induce retinal ischemia and explored the therapeutic mechanism of stem
cell to rescue the mitochondrial dysfunction. We demonstrated that retinal ischemia accompanied
cerebral ischemia, causing cellular degeneration in the eye. We showed that mitochondrial
dysfunction characterized by decreased mitochondrial function, altered mitochondrial network
morphology, and imbalanced mitochondrial dynamics, altogether indicating that impaired
mitochondria are a key contributor to ischemic cell death. Finally, we demonstrated that stem
viii

cell therapy is a potential treatment for retinal ischemia by rescuing mitochondrial dysfunction
via transfer of healthy mitochondria to injured cells. The present work revealed that using stem
cells to target mitochondrial dysfunction represents a potential therapy for cerebral and retinal
ischemia and potentially for other CNS disorders with mitochondrial dysfunction as a rampant
underlying pathology.
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Chapter 1: Introduction
Note to Readers: Portions of this chapter have been previously published in “ Nguyen H, Liska
MG, Crowley MG, Borlongan CV. Stem Cell-Paved Biobridge: A Merger of Exogenous and
Endogenous Stem Cells Toward Regenerative Medicine in Stroke. In: Lapchak PA, Zhang JH,
editors. Cellular and Molecular Approaches to Regeneration and Repair. Cham: Springer
International Publishing; 2018. p. 153-80.”, and has been included with permission from the
publisher.
1.1. Introduction to Stroke and Current Treatment Strategies
Stroke is defined as a pathological state whereby a reduction in blood flow affects one or
more regions of the brain, which may be caused by an obstructed vessel resulting in ischemic
stroke or a ruptured blood vessel leading to hemorrhagic stroke 1. While ischemic stroke is more
common, hemorrhagic stroke has a higher mortality rate 1. Stroke is one of the leading causes of
death and disability in the United States with approximately 800,000 people affected annually 1.
Stroke survivors experience a range of long-term consequences from moderate functional
impairments to severe disability 1. The estimated economic burden of stroke is $34.3 billion
annually including the healthcare cost and loss of productivity, with the projected figure to
increase to $94.3 billion in 2035 1. In fact, the economic burden of stroke has increased due to
improved treatment protocols, resulting in the overall decreased in mortality rate 1. Despite the
prevalence and severity of the economic burden, the therapeutic options for stroke are limited to
tissue-type plasminogen activator (tPA), endovascular interventions, and physical therapies to
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alleviate symptoms 2, 3. Only a small percentage of stroke patients are administered tPA primarily
because of ischemic stroke-related eligibility criteria and its narrow 4.5 hours from onset
therapeutic window, with the risk of hemorrhagic transformation increasing outside the
recommended timeframe 2-5. Similarly, not all patients are qualified for mechanical
thrombectomy due to many factors such as the location of the embolus, time since onset, the
collateral circulation, among others. In addition, endovascular interventions share the same risk
of time-dependent hemorrhagic transformation 2, 6-9. Based on the current state of limited stroke
treatments, patients are left with physical abnormalities, including visual deficits, manifesting as
debilitating symptoms. Therefore, there is a need for innovative and more effective therapies for
both acute and chronic stage of stroke.
1.2. Visual Impairment in Stroke
Visual impairment is one of the factors that limits the likelihood of stroke patients
participating in rehabilitation, displaying functional recovery, and exhibiting an increase quality
of life 10, 11. According to a prospective multicenter cohort study, visual impairments occurs in
92% of stroke patients 12. In another study, 20.5% of stroke patients display persistence visual
impairment at 90 days 13. Furthermore, patients with monocular vision loss exhibit a higher risk
of concurrent ischemic stroke and vice versa 14-19. Retinal ischemia is the major cause of visual
impairment in approximately 16% of the stroke patients; and it is a shared pathology with other
common ocular vascular diseases, such as diabetic retinopathy, glaucoma, retinal vein occlusion,
and central retinal artery occlusion (CRAO) 20-27. In particular, CRAO shares similar
atherosclerosis risk factors with cerebral ischemia 27, 28. Despite many pathological similarities
between retinal ischemia and cerebral ischemia, the underlying mechanisms and the relationship
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between them remain unclear which lead to a lack of effective treatment for retinal ischemia and
stroke as a whole 21, 29.
1.3. Stroke Pathology
In both cerebral ischemia and retinal ischemia, ischemic stroke occurs when there is an
occlusion of an artery, resulting in loss of blood supply to one or more regions. This causes a
reduction in both the oxygen and nutrient supplies. The brain and the eye are one of the most
metabolically active tissues and consume oxygen more than many other tissues 30. Due to the
high demand of oxygen in the brain and eye, the oxygen availability in these tissues is limited by
the blood flow and the consumption rate 30, 31. Even within the retina, the oxygen tension varies
greatly depending on the retinal layer 32, 33. For example, oxygen tension is much higher in the
choroid plexus and lower in photoreceptor and the ganglion cell layers 32, 33. Therefore, these
tissues are highly sensitive to changes in oxygen level such as during hypoxic environment 34, 35.
The nervous system and the retina require a high demand of energy to maintain membrane
potential, trigger action potential, and communicate via chemical synapses 36, 37. Hence, neurons
are sensitive to metabolic stress and susceptible to ischemic insult 38. The lack of energy supply
causes ionic imbalance and mitochondrial damage, increases reactive oxygen species (ROS)
production, and decreases membrane integrity which singly or in tandem contribute to cell death
cascades 39, 40. The cell death after ischemic injury occurs in stages (acute, sub-acute, and
chronic) starting within minutes and extending to hours, even days, weeks and months 41. The
ischemic core, the initial irreversible damaged tissue, is less amenable to therapeutic treatment 42.
The penumbra is the area surrounding the ischemic core in which the cells are under-distress due
to low level of oxygen and nutrients and high level of toxic microenvironment spilled from the
ischemic core 42, 43. The penumbra is an endangered region and could expand into an irreversible
3

injury if left untreated 44. Yet, the penumbra can potentially be rescued and has a wider
therapeutic window making it the ideal target for interventional therapies 41, 44, 45.
1.3.1. Excitotoxicity
Within minutes of an ischemic attack, cells in the ischemic core fail to maintain ionic
homeostasis, leading to acidosis, cell swelling and membrane rupture 46. The necrotic cells
within the infarct core produces a toxic microenvironment. Leaked deleterious substances from
these cells have the capacity to reach adjacent healthy cells and cause harm 47. Ruptured cells
and failure of reuptake mechanisms contribute to high levels of glutamate in the
microenvironment that lead to excitotoxicity in neighboring cells 47, 48. Excess glutamate
prolongs the stimulation of N-methyl-D-aspartate (NMDA) receptors and α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid (AMPA) receptors, further increase influx of Na+, Ca2+ and
water into the cells 49-51. The influx of Na+ and water contributes to cell swelling and edema 49.
Activation of glutamate receptors does not account fully for the increase of intracellular Ca2+. In
fact, Ca2+ can build up the cells through other channels such as Na+/Ca2+ exchanger 52-54, acid
sensing ion channels 55-57 and TRP channels 58, 59. In addition, Ca2+ can be released from
organelles such as mitochondria and the endoplasmic reticulum (further discussion in 1.5). The
excessive calcium influx triggers the activation of proteases, nucleases and lipases which
degrade proteins and essential cellular structures 60. Furthermore, the high level of glutamate and
K+ triggers cortical spreading depolarization (CSD), a phenomenon in which a wave of
depolarization propagates along neurons and astrocytes 61. In fact, CSD has been demonstrated
strongly in stroke patients 62. Since repolarization is a high energy demanding process, CSD
exacerbates the ionic imbalance and hastens the cell death process of cells with limited blood
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supply in the penumbra 63, 64. As a result, CSD contributes to the expansion of the ischemic
infarct core 63.
1.3.2. Oxidative and Nitrative Stress
After the initial insult, there is a surge of ROS and reactive nitrogen species (RNS) 65, 66.
The oxidative and nitrative stress play a key role in the progression of ischemic injury 67, 68.
While a low balanced level of radicals is important for normal function of neuronal cells; overproduction of ROS and RNS after ischemic insult exacerbates cellular damage 67, 69. Excessive
ROS and RNS overwhelm the antioxidant enzymes and damage macromolecules such as
proteins, lipids and nucleotides 70-72. In addition, ROS and RNS also initiate cellular apoptosis
via release of pro-apoptosis factors from mitochondria (further discussion in 1.5) 73. Beside
mitochondria, other enzymes also contribute to the production of ROS, such as NADPH oxidase
(NOX) and nitric oxide synthase (NOS) 74-76. In fact, NOX is implicated as a potent source of
ROS. In fact, ROS from NADPH oxidase kindles further ROS production from mitochondria 75.
Similar to ROS, RNS also has deleterious cellular effects, such as inhibiting mitochondrial
enzymes, facilitating mitochondrial permeability transition pores (mPTPs) formation, causing
deoxyribonucleic acid (DNA) strain breaks, activating PARP and increasing influx of Ca2+ 77. In
particular, nitric oxide (NO) covalently bind to cysteine residues forming S-nitrosothiol
derivatives and altering protein functions 78-80. Taken together, ROS and RNS play an important
role in the stroke pathology.
1.3.3. Neuroinflammation
As we mentioned above, the resulting pathophysiology of stroke extends into chronic
phase, days and weeks after the initial insult. Neuroinflammation and the disruption of the blood
5

brain barrier (BBB) contribute significantly to the secondary cell death process during the
chronic phase of stroke 81, 82. After stroke, neuroinflammation has a bi-phasic response with
double-edged sword effects 83-85. In the acute phase, the activation of microglia and astrocytes
has neuroprotective roles such as removing dead cells, clearing debris, and facilitating tissue
repair 86-88. However, prolonged inflammation perpetuates secondary cell death in chronic phase
89-91

. Neuroinflammation is instigated by damage-associated molecular patterns (DAMPs) which

are released from dead and dying cells 84, 92. Examples of DAMPs are high mobility group box-1
(HMGB1), heat shock proteins, lipopeptides, advanced glycation end-products and hyaluronan
84, 92

. DAMPs activate their receptors such as toll-like receptors (TLRs) which lead to production

of pro-inflammatory cytokines and chemokines via NF-κB signaling pathway 93, 94. In particular,
TLR2 and TLR4 expression have been shown to be upregulated following ischemia and correlate
with infarct volume 95-98. Once the process is initiated, pro-inflammatory cytokines such as tumor
necrosis-alpha (TNF-α), interleukin-1-beta (IL-1β), interleukin-6 (IL-6) and others are released
from various cell types leading to leukocytes infiltration and cell death 93. Studies have
demonstrated that TNF-α and IL-1β promote neutrophil infiltration and exacerbate ischemic
injury 99, 100. For example, TNF-α and IL-1β increase the expression of adhesion molecules
(ICAM-1, P-selectin and E-selectin) in endothelial cells and promotes rolling and sticking of
leukocytes 101-103, which are critical to neuroinflammation-mediated tissue injury. Whereas TNFα antibody and TNF-α binding protein have been shown to decrease infarct volume 104-106, IL-6
exhibit dual roles of pro-inflammation and beneficial for tissue repair 107-111. High level of IL-6
has been shown to elevate body temperature and associate with larger infarct size after stroke 107.
Yet, IL-6 also inhibits TNF-α and promotes tissue remodeling via activation of STAT (signal
transducer and activator of transcription) 108, 109. Furthermore, this stroke-induced inflammatory
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response further exacerbates cell death and BBB breakdown 84, 112. Rampant neuroinflammation
disrupt cell-cell interactions of the neurovascular unit 84. Pro-inflammatory cytokines increase
BBB leakage by altering tight junctions between endothelial cells, pericytes and astrocytes 103.
The damaged BBB allows substances and cells which are normally foreign to the brain to enter
and exacerbate the inflammation response. Finally, as mentioned above, inflammatory cytokines
and chemokines stimulate the expressions of adhesion molecules which facilitate the infiltration
of peripheral immune cells to enter the brain. Altogether, unregulated prolonged inflammation
worsens the hostile ischemic environment and facilitates secondary cell death in the later stage of
stroke.
1.4. Introduction to Mitochondria
Mitochondria are intracellular organelles enclosed by double membrane, creating two
distinct compartments (the intermembrane space and the matrix) 113. The outer membrane has
high permeability, allowing the free movement of ions, water, adenosine triphosphate (ATP),
adenosine diphosphate (ADP) and other small molecules into the intermembrane space 113. On
the other hand, the inner membrane has more restricted permeability compared to the outer
membrane 113. The inner membrane is the center of mitochondrial energy production, containing
the electron transport chain (ETC) enzymes, ATP/ADP transport proteins, and other ion channels
73

. Oxidative phosphorylation (OXPHOS), through ETC, produces the majority of energy in the

form of ATP 73. The ETC comprises of five multi-enzyme complexes (complex I-V) which can
also form supercomplexes in the inner membrane of the mitochondria 114. The electrons carried
by NADH and FADH2 are fed into the ETC at complex I and II to initiate the process 114.
Complex I, III, and IV use the electrons to pump protons from the mitochondrial matrix into the
intermembrane space, creating the electrochemical gradient for ATP production 73, 115. Soluble
7

cytochrome c facilitates the transfer of electrons from complexes III to complex IV, the final
electron acceptor 116. The proton motive force drives the ATP synthesis of complex V 116.
Mitochondria not only produce energy in the form of ATP but also participate in maintaining
homeostasis of the cells, regulating metabolism, apoptosis, and modulation of inflammation 117123

. Hence, mitochondrial dysfunction has been implicated as a key contributor to disease

progress in stroke and other neurological disorders. In fact, mitochondrial dysfunction has been
studied in stroke and in various neurological diseases e.g. fragile x-associated tremor/ataxia
syndrome, Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease 41, 124129

, and retinal ischemia and optic neuropathy 130-133.

1.5.

Mitochondrial Dysfunction in Stroke
The central nervous system (CNS) consumes approximately 20% of the body’s total

energy production 36, 134. The majority of the generated energy is used to maintain the membrane
potential, initiate action potential and communicate with other cells via chemical synapses 36.
With the sudden loss of oxygen and energy supply in cerebral ischemia/retinal ischemia,
mitochondria, the powerhouse of the cells, cannot maintain sufficient ATP production. As
previously discussed, the lack of energy leads to disruption in membrane integrity, ionic
imbalance and necrosis. Moreover, this failure of energy supply triggers a cascade of events lead
to cell death and places mitochondria in the center of cerebral and retinal ischemia pathology.
Therefore, dysfunctional mitochondria with altered bioenergetics will have detrimental effects to
the cells and the CNS.
Under normal condition, small amount of ROS is produced during OXPHOS. The
leakage of electrons at the sites, predominantly complex I and III, leads to the production of ROS
such as superoxide, hydrogen peroxide, hydroxyl radical etc. 135-137. As previously mentioned,
8

low level of ROS is important for cellular function and cells have developed antioxidant
enzymes to maintain the redox homeostasis such as superoxide dismutase (SOD), glutathione
peroxidase (GSHPx), glutathione reductase, and glutathione-S-transferase (GSH) 138, 139. Under
hypoxic environment such as ischemic stroke, mitochondria produce high amount of ROS that
overwhelm the antioxidant defense and damages macromolecules such as proteins, lipids, and
nucleotides 73, 140.
Mitochondria also play a major role in initiating apoptosis pathways 73, 141. Damaged
mitochondria caused by energy failure, intracellular Ca2+ overload, membrane depolarization,
and ROS can initiate the apoptosis process through the release of cytochrome c, apoptosisinducing factor (AIF), and Smac/DIABLO into cytosol via mPTPs 142. Accumulation of Ca2+
cleaves B-cell lymphoma-2 (Bcl-2) interaction domain which in turn interacts with pro-apoptotic
proteins to open mPTPs. A transient opening of mPTPs further releases pro-apoptotic substances
(e.g. cytochrome c and AIF) into the cytosol and collapse the mitochondrial membrane potential.
Cytosolic cytochrome c interacts with apoptotic-protease-activating factor-1 (Apaf-1) to activate
pro-caspase-9, which in turn activates caspase-3 143, 144. Activation of caspase-3 leads to
mitochondrial membrane depolarization, DNA fragmentation and chromatin condensation.
Conversely, Smac/DIABLO activates caspases by inhibiting inhibitor-of-apoptosis proteins
(IAPs), which inhibit pro-caspase activation under normal condition 145, 146. Upon translocation
from the mitochondrial outer membrane to the nucleus, AIF accelerates apoptotic process
through DNA fragmentation and chromatin condensation 147, 148. Bcl-2 protein family is another
pathway that regulates apoptosis. Bcl-2 proteins can be classified into pro-apoptotic proteins
such as Bax, Bid, Bad etc. or anti-apoptotic proteins such as Bcl-2, Bcl-xL, and Bcl-w 73, 149, 150.
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Mitochondria are not a static organelles. In fact, mitochondria constantly undergo fission
and fusion and alter the morphology of the mitochondrial network 151-153. Mitochondrial fission is
the process in which mitochondria constrict and divide whereas mitochondrial fusion is merging
of mitochondria. Dynamin-related protein 1 (Drp1), an important regulator of mitochondrial
fission, is recruited to the outer membrane of mitochondria 154, 155. In combination with other
proteins such as dynamin 2, Drp1 form a ring-like structure prior to splitting mitochondria 156, 157.
On the other hand, there are several crucial proteins that participate in the process of
mitochondria fusion such as optic atrophy protein 1 (OPA1) and mitofusin 1 and 2 (Mfn1 and
Mfn2). Mitochondrial fission and fusion dynamics are essential for maintaining homeostasis of
mitochondria. Mitochondrial fission facilitates the clearance of damaged proteins and
mitochondrial DNA (mtDNA) via mitophagy 158. Moreover, in neuronal cells, mitochondrial
fission is essential for transportation of mitochondria to long distance destination such as axon
terminals and dendrites 159. In contrast, mitochondrial fusion enhances the mitochondrial
functions by sharing the metabolites across the network, exchanging mtDNA, and allowing the
production of ATP more efficiently 160, 161. Studies have demonstrated that ischemic injury alters
mitochondrial dynamics characterized by an upregulation of Drp1, resulting in an increased
mitochondria fission 162. Accordingly, mitochondria become fragmented and dysfunctional in
ischemic cells 162, 163. Studies have shown that decreased Drp1 expression reduces mitochondrial
ROS production and limits infarct volume 164, 165. Conversely, Mfn2 expression has been
reported to be decreased in ischemic cells, while inhibition of Mfn2 and OPA1 further
exacerbates cell death 166. Therefore, maintaining the balance between mitochondrial fission and
fusion is critical to the survival of cells especially under pathological condition such as stroke.
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Mitochondria also play an important role in modulating inflammation. Damaged
fragments of mtDNA are released into the cytosol and act as DAMP, triggering inflammation 167.
In particular, fragmented mtDNA activates TLR9, triggering NF-κB inflammation signaling
pathway 167, 168. In addition, mtDNA also leads to the activation of NLRP3 inflammasome which
promotes the cleavage of pro-IL-1β to pro-inflammation IL-1β 169. Indeed, studies have
demonstrated that NLRP3 protein level is increased together with elevated IL-1β and IL-18 level
after ischemic stroke 170, 171. Conversely, studies have shown that NLRP3-deficient mice or
suppressing NLRP3 with immunoglobulin reduces infarct size and behavioral deficits 170.
In particular, mitochondria’s role as the powerhouse of the cellular machinery serves as
the crux of maintaining homeostasis and its dysfunction plays a key role in cerebral and retinal
ischemia pathology 172-178. Understanding the contribution of mitochondrial dysfunction in
retinal ischemia pathology may provide mechanistic and translational insights into developing
more effective treatments for stroke and other disorders with retinal ischemia pathology.
Therapeutic strategies such as stem cell therapy that reverse mitochondrial dysfunction could be
valuable options for retinal ischemia and other neurological disorders with mitochondrial
pathology.
1.6. Introduction to Stem Cells
Stem cells are a class of cells which share specific characteristics such as self-replication,
differentiation, and expression of specific cell markers 179. Stem cells can preserve their
characteristics via self-replicating and can be found within several niches of the body 179. The
differentiation capability of stem cells allow them to regenerate and maintain the homeostasis of
the body 180. For example, bone marrow stem cells rejuvenate the red blood cells population in
the body. Stemness is the term coined to describe the capacity of stem cells to self-replicate and
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differentiate into various lineages 181. Stem cells are often classified based on their origin of
harvest and their potency (e.g. totipotent, pluripotent, or multipotent) 182. For example, adult
adipose multipotent stem cells are found in fat tissue and can differentiate into limited number of
cell types in the same lineage. In addition, stem cells can also be classified further based on
expressed cell markers. For example, Bone marrow-derived mesenchymal stem cells are positive
for CD29, CD44, CD105, CD73, CD90, CD106, and CD166 markers, while negative for CD14,
CD34 and CD45 183, 184.
1.6.1. Stem Cells for Neurological Disorders
Since their discovery, stem cells have been studied as a potential therapeutic treatment for
many neurological disorders such as stroke, traumatic brain injury (TBI), amyotrophic lateral
sclerosis, AD, and PD 185-191 and ocular degenerative diseases such as glaucoma, age-related
macular degeneration, retinitis pigmentosa, and diabetic retinopathy 192-199. There are some
ongoing limited clinical trials using stem cells therapy for neurological disorders, including
stroke 200, 201. Despite early belief, stem cells exist in adulthood and contribute to the homeostasis
of the body 202-204. To date, the well-established mechanism of action of stem cells are cell
replacement 205-208 and bystander effects (secretion of neuroprotective, neuroregenerative, antiinflammatory molecules, and others) 209-216. The initial concept is that transplanted stem cells
could replicate and differentiate to replace dead/dying cells. However, studies have shown that
this notion of cell replacement may not be the optimal regenerative mechanism of stem cells 217,
218

. Only small amount of transplanted stem cells survive despite best effort to control for

immunogenicity through autologous transplant or using immunosuppressant drugs 219. To further
discredit the cell replacement mechanism, even smaller amount of transplanted cells can
differentiate into neuronal cells in vivo models 207, 208. One possible explanation for the
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phenomenon is that the hostile microenvironment of the disease brain does not support the
survival, differentiation and maturation of stem cells. Moreover, the observation of neural
network repair and functional integration of transplanted cells with the host cells remain elusive.
Therefore, cell replacement may not be a major contributor to observed functional benefits of
cell transplantation. Instead, accumulating studies support the bystander effects of stem cells in
which secreted trophic factors and cytokines are the major contributors to the therapeutic
mechanism of stem cells 211. For example, in animal studies, bone marrow-derived mesenchymal
stem cells secrete a variety of trophic factors (e.g. vascular endothelial growth factor, brainderived neurotrophic factor, nerve growth factor, insulin growth factor-1, and hepatocyte growth
factor) which promote the neuroregeneration process 213, 214. In addition to growth factors, stem
cells secrete microvesicles and exosomes containing anti-inflammatory cytokines to modulate
inflammation 215, 220-222. In fact, the current consensus has shifted from cell replacement paradigm
toward bystander effect 223. However, both mentioned mechanisms cannot explain whole
spectrum of observed benefits. For example, both mechanisms do not fully account for the
endogenous tissue recovery effect observed after transplantation. To this end, recent studies from
our laboratory have proposed a third mechanism in which exogenous stem cells facilitate the
migration of endogenous stem cells from neurogenic niches to injured area 224, 225. Moreover, the
effect of stem cells on mitochondrial dysfunction remains to be fully investigated.
1.6.2. Targeting Mitochondrial Dysfunction using Stem Cells
Recent studies have shown that using stem cells to treat diseases characterized by
mitochondrial dysfunction is a novel and promising approach for stroke. In particular, the
concept of mitochondrial transfer between mammalian cells is intriguing and has been reported
by many studies summarized in a recent review 226. However, the underlying mechanism remains
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unclear and many early studies focus in non-nervous systems 227-231. Only recently, a study has
demonstrated that astrocytes transfer mitochondria to neurons after stroke in both in vitro and in
vivo 232. The stimulated astrocytes, via CD38/cyclic ADP ribose signaling, secrete extracellular
mitochondria which provide therapeutic benefits for ischemic neurons 232. Currently proposed
mechanisms for the mitochondrial transfer involve tunneling nanotubes (TNTs), extracellular
vesicles (EVs), gap junctions and cell fusion 228, 233-235. TNTs are thin and long structures
comprised of actin and microtubules that allow two separated cells to connect with each other 235,
236

. On this note, Miro1, a Rho GTPases, plays a significant role in regulating the transfer of

mitochondria through TNTs 227, 229. Bone marrow-derived stromal stem cells form connexin-43
containing gap junction with alveolar epithelial cells 228. This gap junction facilitates the transfer
of mitochondria and increases ATP production in alveolar cells after LPS insult 189, 228. Cell
fusion is another way in which stem cells can transfer mitochondria to recipient cells. Human
MSCs have shown to fuse with injured respiratory tract epithelial cells 233. In a separate study,
bone marrow-derived cells are shown to fuse with cardiomyocytes, hepatocytes and Purkinje
neurons 237. Recent studies have shown that mitochondria can be transported via EVs, yet the
detailed processes associated with such uptake with EVs remains to be investigated 122, 238. Of
note, such transfer of mitochondria from stem cells to retinal cells and its mechanisms
correspond to the main objectives of the present study on stroke-induced retinal ischemia.
1.7. Summary and Hypothesis
Stroke remains to be one of the leading causes of death and disability in America and
contributes a significant social and economic burden to the society 1. Approximately, 16% of
stroke patients suffer retinal ischemia but it is often overlooked and under-reported 14. Visual
impairments negatively affect functional ability, the likelihood of participation in rehabilitation,
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and the quality of life of stroke patients 20. The underlying mechanisms of retinal ischemia and
their relation with cerebral ischemia are not fully understood, resulting in limited holistic
therapeutic treatment for stroke patients. Mitochondria play crucial roles in the cell homeostasis
and function, such as energy production, regulating metabolism, apoptosis, cell cycle, calcium
homeostasis, generation of ROS, and modulating inflammation 117, 118. Mitochondrial
dysfunction has been linked to multiple neurological diseases including stroke, AD, PD, and TBI
118

. However, the role of mitochondrial dysfunction in retinal ischemia remains to be

investigated. For the past few decades, stem cell therapy has emerged as a promising therapeutic
approach to treat various neurological disorders. In particular, multiple pre-clinical studies have
demonstrated the benefits of stem cell therapy for ischemic stroke 216, 239, 240. In addition, limited
clinical trials of stem cell therapy for stroke have commenced over the last five years. Hence,
stem cell therapy might pose as a potential therapeutic approach for retinal ischemia, which often
accompanies cerebral ischemia. Despite decades of research, the mechanism(s) of stem cell
therapy is not fully elucidated and remains as a fundamental gap in our knowledge. An
elucidation of stem cell mechanism of action may improve the safety and efficacy, and advance
the clinical application of stem cell therapy. Understanding the role of mitochondria dysfunction
in retinal ischemia may provide insights into the stroke pathology and offer a mechanism of stem
cell therapy, altogether providing the basis for developing an improved therapeutic strategy for
stroke patients.
The overarching hypothesis of the present study is that mitochondrial dysfunction is an
important factor in causing ganglion cell degeneration in retinal ischemia in vitro and in vivo
models, and targeting this organelle via stem cell therapy may rescue the mitochondrial deficits
and reverse pathology of retinal ischemia. The present study aims to fill the gap in our current
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knowledge about the pathology underlying retinal ischemia and stroke, as well as in elucidating a
potential mechanism of stem cell therapy. Understanding the role of mitochondrial dysfunction
in retinal ischemia and whether mitochondria also play a key role the therapeutic mechanism
underlying stem cell therapy will provide new insights into the pathology of retinal ischemia, as
well as cerebral ischemia and other CNS disorders characterized by altered mitochondrial
function and morphology, altogether forming the basis to develop an improved treatment for
these diseases via mitochondria-mediated therapeutic strategies.
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Chapter 2: Middle cerebral artery occlusion (MCAO) reduces blood flow to brain and eye
and induces retinal ganglion cell loss
Note to Readers: Portions of this chapter have been previously published in “ Nguyen H, Lee
JY, Sanberg PR, Napoli E, Borlongan CV. An eye opener in stroke: Mitochondrial dysfunction
and stem cell repair in retinal ischemia. In Press.”, and has been included with permission from
the publisher.
2.1. Background
The most frequently used experimental models to study retinal ischemia involve
intraocular pressure (IOP) or permanent ligation of posterior ciliary vessels/optic nerve. While
these methods induce retinal ischemia, they do not reflect the dynamics of cerebral and retinal
ischemic in stroke patients. Only few studies have examined the retinal ischemia in stroke
models, such as MCAO 241, 242. Here, we investigated whether retinal ganglion cell degeneration
accompanied the MCAO stroke model.
2.2. Methods
2.2.1. Middle Cerebral Artery Occlusion
Adult male Sprague-Dawley rats (approximately 250g) were anesthetized by a mixture of
1–2% isoflurane in nitrous oxide/oxygen (69%/ 30%) via face mask. Body temperature was
maintained at 37 ± 0.3 °C during the surgical procedures. The midline skin incision was made in
the neck with subsequent exploration of the right common carotid artery (CCA), the external
carotid artery, and internal carotid artery. A 4-0 monofilament nylon suture (27.0–28.0 mm) was
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advanced from the CCA bifurcation until it blocked the origin of the middle cerebral artery
(MCA). The contralateral CCA was temporally ligated for 10 minutes to ensure a consistent
blood flow occlusion (including collaterals) to the brain. Animals were allowed to recover from
anesthesia during MCAO. After 60 minutes of transient MCAO, animals were re-anesthetized
with 1–2% isoflurane in nitrous oxide/oxygen (69%/30%) using a face mask and reperfused by
withdrawal of the nylon thread. Animals receiving the sham operation were anesthetized with 1–
2% isoflurane in nitrous oxide/oxygen (69%/30%) via face mask. A midline incision was made
in the neck and the right CCA was isolated. The animals were then closed and allowed to recover
from anesthesia.
2.2.2. Laser Doppler Blood Flow Measurement
Brain and eye retinal blood flow measurements were obtained using a laser Doppler
(Perimed, Periflux System 5000). Each animal was placed under deep anesthesia during the
measurement and the animal’s head was shaved for brain measurement. For measurement of
brain perfusion, the laser Doppler probe was placed over the right frontoparietal cortical area
supplied by the MCA. For measurement of eye perfusion, the laser Doppler probe was placed
over the retina of the right eye. Measurements were made at baseline, during MCAO, and 5minutes after reperfusion. Ophthalmic ointment was applied and the animals were closely
monitored during their recovery from anesthesia.
2.2.3. Optic Nerve Measurement & Immunohistochemistry
On the day of tissue collection, the animals were euthanized with CO2 and perfused with
0.9% saline. The animals’ eyes were quickly harvested and the retina were isolated in ice cold
phosphate-buffered saline (PBS), pH 7.4. The optic nerves and the retinas were fixed with 4%
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paraformaldehyde (PFA; 158127; Sigma) in PB for 2 hours at 4°C. The tissues were washed
with ice cold PBS for several times and kept in this solution at 4°C.
The retinas were embedded in 4% agarose and sectioned with a vibratome at 30 μm
thickness in ice cold PBS. The tissues were incubated in blocking buffer (5% normal goat serum
and 0.1% Tween 20 in PBS) for 3 hours at 4°C. The tissues were then incubated with NeuN
(1:500; ab104225, Abcam) in blocking buffer at 4°C overnight. Thereafter, the tissues were
washed three times with PBS followed by incubated with Alexa 488 secondary antibody (1:500)
for 4 hours at 4°C. The tissues were further washed three times with PBS and mounted with antifade mounting medium containing 4,6-diamidino-2-phenylindole (DAPI) (H-1500; Vector
Laboratories)
2.3. Results
2.3.1. MCAO Reduces Blood Flow to Brain and Eye
We initially investigated whether MCAO caused a reduction in blood flow to the brain,
as well as to the eye. Laser Doppler was used to measure blood flow to brain and eye at baseline,
during MCAO and 5-minute after reperfusion (Figure 2.1). At baseline, there were no significant
differences between the control group and MCAO group in the laser Doppler measurements of
ipsilateral hemisphere, contralateral hemisphere, or ipsilateral eye (311±23 and 316±87; 296±49
and 282±18; and 592±67 and 614±81, respectively, unpaired t-tests p(s)>0.05). During MCAO,
there were significant differences between the control group and MCAO group in the percentage
of blood flow to the contralateral hemisphere, ipsilateral hemisphere, and ipsilateral eye
compared to the baseline (unpaired t-tests p(s)<0.05) (Table 2.1). The differences in the
percentage of blood flow to the ipsilateral hemisphere and ipsilateral eye remained significant at
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5-minutes after reperfusion between the control group and MCAO compared to the baseline
readings (unpaired t-tests p(s)<0.05) (Table 2.1). Altogether, these results indicate that MCAO
caused a significant reduction in blood flow to the eye which mirrored the blood flow reduction
in the brain.

Figure 2.1: MCAO reduced blood flow to brain and eye. Laser Doppler was used to measure
blood flow to brain and eye at baseline, during MCAO, and 5-minute after reperfusion. (A) At
baseline, there were no differences in blood flow measurements of the ipsilateral hemisphere,
contralateral hemisphere, or ipsilateral eye between the control and MCAO group. (B) During
MCAO, there were significant reductions in blood flow to brain and eye in the MCAO group
compared to the control group. (C) The blood flow to ipsilateral hemisphere and ipsilateral eye
remained reduced compared to the control at 5-minute after reperfusion. There was no significant
difference in blood flow to the contralateral hemisphere between the MCAO and the control at 5minute after reperfusion. Unpaired t-test(s) *** p<0.001; ** p<0.01; * p<0.05. Bar graphs
represent mean ± SEM (n=6). Contra: contralateral; Ipsi: ipsilateral
Table 2.1: Percent blood flow during MCAO or 5-minute after reperfusion compared to baseline
readings in different regions of control and stroke animals. Contra: contralateral; Ipsi: ipsilateral

Contra. Hemisphere
Ipsi. Hemisphere
Ipsi. Eye

During MCAO vs. Baseline
Control
MCAO
89.4±27.0 %
29.2±17.0 %
83.9±12.2 %
14.9±8.64 %
96.9±15.7 %
32.1±14.4 %

5-minute After Reperfusion vs. Baseline
Control
MCAO
110.5±29.1 %
72.9±26.0 %
103.2±5.82 %
36.9±19.9 %
103.5±9.41 %
63.9±23.3 %

2.3.2. MCAO Induces Ganglion Cell Loss and Optic Nerve Degeneration at Day 3 and Day 14
We next examined whether the reduction in blood flow to the eye during MCAO caused
significant ganglion cell loss and optic nerve degeneration in stroke animals. There were
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significant reductions in ganglion cell at day 3 and day 14 in the ipsilateral eye compared to
sham group (post-hoc test p(s)<0.001; Figure 2.2). In addition, there were significant reductions
in the ipsilateral optic nerve width of stroke animals compared to the contralateral or sham
animals at day 3 and day 14 (post-hoc test p(s)<0.001; Figure 2.3). ANOVA and post-hoc
statistical analysis is summarized in Table 2.2.

Figure 2.2: MCAO induces ganglion cell loss in the retina at day 3 and day 14. Representative
images of NeuN immunohistochemical staining for ganglion cells of the retina (A) horizontal (B)
cross-section view. (C) Quantification graphs of ganglion cell count at day 3 and day 14. There
were significant ganglion cell deaths in the ipsilateral eyes compared to contralateral eyes or
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sham animals at day 3 and day 14. ANOVA with Bonferroni’s post-hoc test ***p<0.001. Bar
graphs represent mean ± SD (n=6). Scale bar 50 µm. Contra: Contralateral; Ipsi: Ipsilateral

Figure 2.3: MCAO reduces optic nerve width at day 3 and day 14. Optic nerves were captured
with bright field microscope near the optic nerve head. (A) Representative images of the optic
nerves. (B) Quantification graphs of optic nerve width at day 3 and day 14. There were
significant reductions in ipsilateral optic nerve width compared to contralateral or sham at day 3
and day 14. Contra: Contralateral; Ipsi: Ipsilateral. ANOVA with Bonferroni’s post-hoc test
*p<0.05; ***p<0.001. Bar graphs represent mean ± SD (n=6). Scale bar 0.5 mm.
Table 2.2: ANOVA with Bonferroni’s post-hoc test of the optic nerve width and ganglion cell
density between sham and MCAO animals at day 3 and day 14.

Day 3
Day 14

Optic Nerve Width
Sham
Contralateral
F(2,15)=13.97,
F(2,15)=13.97,
p=0.0004, post-hoc
p=0.0004, post-hoc
test p<0.001
test p<0.001
F(2,15)=37.33,
F(2,15)=37.33,
p<0.0001, post-hoc
p<0.0001, post-hoc
test p<0.001
test p<0.001
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Ganglion Cell Count
Sham
Contralateral
F(2,15)=16.24,
F(2,15)=16.24,
p=0.0002, post-hoc
p=0.0002, post-hoc test
test p<0.001
p<0.001
F(2,15)=98.33,
F(2,15)=98.33,
p<0.0001, post-hoc
p<0.0001, post-hoc test
test p<0.001
p<0.001

2.4. Conclusion
In this study, we examined whether MCAO stroke model induces retinal cell
degeneration. We demonstrated that MCAO caused significant blood flow reductions to brain
and ipsilateral eye. The blood flow was detected to be reduced in the ipsilateral hemisphere and
the ipsilateral eye at 5-minute after reperfusion. This reduction in perfusion likely contributed to
the significant ganglion cell death and optic nerve degeneration at day 3 and day 14. Our results
support the idea that retinal ischemia can occur in conjunction with cerebral ischemia. Due to the
anatomical juxtaposition of the ophthalmic artery to the MCA, blood flow to the ophthalmic
artery is easily hindered in the event of MCAO stroke thereby causing retinal ischemia. Since
MCAO is the most common form of stroke in human patients, the incidence of retinal ischemia
occurring with cerebral ischemia is likely high. Retinal ischemia is a major predisposing factor
of visual impairment and it is a shared pathology with other common ocular vascular diseases1521

. Understanding the underlying mechanism of retinal ischemia may lead to better treatments for

stroke patients with cerebral and retinal ischemia.
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Chapter 3: Mitochondrial dysfunction is a key factor in retinal cell degeneration as
evidenced by in vitro stroke model
Note to Readers: Portions of this chapter have been previously published in “ Nguyen H, Lee
JY, Sanberg PR, Napoli E, Borlongan CV. An eye opener in stroke: Mitochondrial dysfunction
and stem cell repair in retinal ischemia. In Press.”, and has been included with permission from
the publisher.
3.1.

Background
As previously discussed, mitochondria play a significant role in cellular homeostasis,

regulating apoptosis and modulation of inflammation. Therefore, it is important to assess the
morphology and function of mitochondria in ischemic retinal cells. Here we utilized an in vitro
stroke model to evaluate the role of mitochondrial dysfunction in retinal ischemia.
3.2.

Methods

3.2.1. Retinal Pigmented Epithelium (RPE) Cell Culture
RPE (CRL-4000; ATCC) cells were cultured in Dulbecco’s Modified Eagle Media/F-12
(DMEM/F-12, 11320033; Gibco) containing 10% fetal bovine serum (FBS; FBS001;
Neuromics) and 0.01 mg/ml hygromycin B (10687010; Gibco) in incubator (37°C humidified,
with 5% CO2, 95% air).
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3.2.2. Oxygen Glucose Deprivation (OGD): A Cell Culture Stroke Model
A day prior to the experiment, RPE cells were seeded at 1.5x105 cells/well in 6-well
plate. On the day of experiment, the media of the RPE cells was changed to Dulbecco’s
phosphate-buffered saline (DPBS; 14040133; Gibco). The cells were placed in a sealed hypoxia
incubator chamber (27310; StemCell Technologies) containing 95% N2 and 5% CO2) for 3
hours, mimicking the ischemic stroke. We chose 3 hours because based on our experience with
RPE cells, 3 hours OGD provided 50-60% cell death. After the 3-hour period, fresh media was
reintroduced and the cells were incubated in normoxia condition (37°C humidified atmosphere
containing 5% CO2) for 24 hours, which simulated the reperfusion phase in clinical setting.
3.2.3. Mitochondrial Respiration Assay
On the day of experiments, RPE cells were detached from cell culture plates and seeded
to a Seahorse 96-well plate (101085-004; Agilent) coated with Poly-D-lysine (100µg/ml; P7886;
Sigma) at 5.0 x 104 cells/well. The cells were immobilized by centrifugation method. Briefly, the
Seahorse 96-well plate was centrifuged in swing bucket rotator with slow acceleration (4 on a
scale of 9) to a max speed of 450 rpm with 0 brake. Afterwards, the plate orientation was
reversed and centrifuged again to max speed of 650 rpm with 0 brake. To determine cellular
oxygen consumption rate (OCR), the Seahorse extracellular flux analyzer XFe96 (102416;
Agilent) was used in combination with sequential injection of various compounds (1 µmol/L
oligomycin, 1 µmol/L carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), 0.5
µmol/L Rotenone and Antimycin A). OCR measurements were performed according to the
manufacturer’s protocol.
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3.2.4. Mitochondrial Network Analysis
The RPE cells were stained with MitoTracker (500 ηmol/L; M22426; Invitrogen) for 30
minutes in an incubator (37°C humidified, with 5% CO2, 95% air). Thereafter, the cells were
carefully washed 3 times with DPBS, pH 7.4 to remove any excess dye residue. The cells were
fixed with 4% PFA at room temp for 30 minutes. Finally, the cells were washed with DPBS and
covered with anti-fade mounting medium containing DAPI (H-1500; Vector Laboratories).
Images were captured using an Olympus FV1200 Spectral Inverted Laser Scanning Confocal
Microscope and analyzed using ImageJ (NIH) with mitochondrial network analysis (MiNA)
plugin.
3.2.5. Mitochondria Live Cell Imaging
The mitochondria of RPE cells were incubated with either mitochondrial membrane
potential probe JC-1 (2 µg/mL; T3168; Invitrogen) or with MitoTracker (500 ηmol/L; M22426;
Invitrogen) for 30 minutes in an incubator (37°C humidified, with 5% CO2, 95% air). Next, the
cells were carefully washed 3 times with PBS, pH 7.4 to remove any excess dye residue. Finally,
the media was changed to DMEM without phenol red (21063029, Gibco). Live images were
captured at using an Olympus FV1200 Spectral Inverted Laser Scanning Confocal Microscope.
3.2.6. Immunocytochemistry
The RPE cells were rinsed 3 times with DPBS and then fixed with 4% PFA for 20
minutes at room temperature. The cells were rinsed again for 3 times and permeabilized with
0.3% Triton-X (X100; Sigma) for 5 minutes at room temperature. The cells were rinsed again a 3
times and incubated with blocking buffer containing 5% goat serum (50062Z; Invitrogen) at
room temperature for 60 minutes. The cells were incubated with primary antibodies either rabbit
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anti Ki67 (1µg/ml; NCL-Ki67P; LeicaBiosystems), at 4°C overnight. After rinsing several times
with DPBS, the cells were incubated with Alexa Fluor 488 goat anti-mouse (Life Technologies)
or Alexa Fluor 488 goat anti-rabbit for (Life Technologies) 60 minutes at room temperature. The
cells were then rinsed with DPBS and covered with anti-fade mounting medium containing
DAPI (H-1500; Vector Laboratories).
3.3.

Results

3.3.1. OGD Causes Mitochondrial Respiration Deficits in RPE Cells
In order to evaluate the mitochondrial respiration capacity after ischemia, RPE cells were
exposed to either normal condition or OGD. RPE cells’ mitochondrial respiration was analyzed
using Seahorse XFe96 extracellular flux analyzer (Figure 3.1). OGD caused significant reduction
in the overall RPE cells’ mitochondrial respiration compared to control characterized by
decreased basal respiration (13.8±2.3 and 25.1±1.7, respectively; unpaired t-test p<0.001),
reduced spare respiratory capacity (13.1±3.0 and 24.8±2.0, respectively; unpaired t-test
p<0.001), suppressed proton leak (1.4±0.7 and 5.0±0.7, respectively; unpaired t-test p<0.001),
and lower ATP production (12.5±2.0 and 20.1±1.3, respectively; unpaired t-test p<0.001).
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Figure 3.1: OGD causes significant mitochondrial respiration deficits. RPE cells’ mitochondrial
respiration was analyzed using Seahorse XFe96 extracellular flux analyzer. The OCRs were
measured at baseline and after sequential injections of compounds (1 µmol/L oligomycin, 1
µmol/L FCCP, 0.5 µmol/L Rotenone and Antimycin A). OGD causes significant reductions in
basal respiration, spare respiratory capacity, proton leak and ATP production compared to
control. Oligo: Oligomycin; FCCP: carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone;
Rot/AA: Rotenone and Antimycin A. Unpaired t-test ***p< 0.001. Bar graphs represent mean ±
SEM control (n=11), OGD (n=12).
3.3.2. OGD Alters RPE Cell’s Mitochondrial Network Morphology
We further investigated the effect of OGD on mitochondrial network morphology. RPE
cells’ mitochondrial network was analyzed using immunocytochemistry and ImageJ with MiNA
plugin (Figure 3.2). The measured parameters were previously described 243. In brief, an
individual is defined as mitochondria that do not have a junction and thus are either punctate or
tubular depending on their circularity. Circularity (0 to 1) is a measurement of the shape of
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mitochondria with 1 rated as being perfectly circular. A network is defined as mitochondria
containing at least 1 junction exhibiting one or multiple branches. Mean network branches is the
average number of branches per network while mean branch length is the average length of all
rods/branches. Finally, footprint is the averaged total area with mitochondrial expression based
on normalized intensity. Compared to control, OGD caused a significant reduction in total
mitochondria footprint (38.9±12.3 and 52.4±21.0, respectively; unpaired t-test p<0.001),
decreased in total individual mitochondria (58.8±20.1 and 83.1±26.8, respectively; unpaired ttest p<0.0001), decreased in number of network (6.59±2.80 and 9.00±3.97, respectively;
unpaired t-test p=0.0087), and decreased in average branch length (0.79±0.10 and 0.91±0.13,
respectively; unpaired t-test p<0.0001) while increased significantly the circularity of the
mitochondria (0.53±0.07 and 0.45±0.06, respectively; unpaired t-test p<0.0001). Altogether
these results demonstrate that OGD significantly altered the mitochondrial network morphology
towards an impaired state, i.e., fragmented circular mitochondria.
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Figure 3.2: OGD alters RPE cell’s mitochondrial network morphology. Representative images of
RPE cells stained with MitoTracker (A) live cell imaging with bright field; scale bar 30 µm (B)
immunocytochemical staining with DAPI; scale bar 10 µm. (C) Quantification of RPE cells’
mitochondrial network morphology. Compared to the control, OGD caused significant
reductions in mitochondrial footprint, number of networks, total individual mitochondria, mean
branch length and mean network branches while increased the circularity of mitochondria.
Unpaired t-test *p<0.05;**p<0.01;***p<0.001. Bar graphs represent mean ± SEM control
(n=52), OGD (n=45).

30

3.4.

Conclusion
In summary, we demonstrated that ischemia causes significant mitochondrial dysfunction

characterized by an overall decreased in mitochondrial function and altered mitochondrial
network morphology toward impaired state. Mitochondrial respiration assays revealed that OGD
caused significant deficits to the mitochondrial bioenergetics machinery. In particular, after
OGD, mitochondria were not able to produce as much ATP (ATP production) and had less
ability to respond to energy stress (spare respiratory capacity). As previously discussed,
mitochondria (and its ATP production) represent not only as the energy source of the cells, but
also play a crucial role in regulating apoptosis. Therefore, maintaining sufficient level of ATP is
crucial for cellular homeostasis especially in ischemic cells. In addition, OGD massively altered
the mitochondria network morphology. As previously described, mitochondrial network is
essential for maintaining mitochondrial functions. Mitochondrial network protects mitochondrial
DNA integrity, improves respiratory capacity, exchanging materials, and response to energy
demand or cellular stress. The overall morphology of mitochondrial network depends on the ratio
of mitochondrial fusion and fission. In healthy cells, the balance ratio of mitochondrial fusion
and fission allows mitochondria to display a tubular shape and form interconnected network.
Conversely, low ratio of fusion to fission creates fragmented spherical mitochondria. In the
present study, we demonstrated that OGD shifted the RPE cells’ mitochondrial network to
impaired state i.e. fragmented circular mitochondria. For example, there were significant
reductions in total number of mitochondria (footprint) and numbers of mitochondrial network in
OGD cells compared to control. Within the mitochondrial network, there were less and shorter
branches in OGD cells compared to control. Outside of the mitochondrial networks, there were
less overall mitochondria (individuals) and they exhibited more spherical shape (higher
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circularity). Taken together, ischemia altered the mitochondrial network to impaired state as
evidenced by fragmented, spherical mitochondria.
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Chapter 4: MSCs ameliorate retinal cell loss and rescue mitochondrial function possibly
via transfer of mitochondria
Note to Readers: Portions of this chapter have been previously published in “ Nguyen H, Lee
JY, Sanberg PR, Napoli E, Borlongan CV. An eye opener in stroke: Mitochondrial dysfunction
and stem cell repair in retinal ischemia. In Press.”, and has been included with permission from
the publisher.
4.1.

Background
As previously discussed, many studies have demonstrated the use of MSCs as promising

cell-based therapy option for ischemic stroke 186-193. Here, we explored the potential therapeutic
effects of MSCs on retinal ischemia utilizing in vivo and in vitro stroke models. We hypothesized
that MSCs could attenuate the retinal cell loss caused by ischemia by restoring mitochondrial
function and morphology. We also investigated a potential underlying mechanism in which
MSCs transfer healthy mitochondria to injured retinal cells.
4.2.

Methods

4.2.1. Middle Cerebral Artery Occlusion
Adult male Sprague-Dawley rats (approximately 250g) were anesthetized by a mixture of
1–2% isoflurane in nitrous oxide/oxygen (69%/ 30%) via face mask. Body temperature was
maintained at 37 ± 0.3 °C during the surgical procedures. The midline skin incision was made in
the neck with subsequent exploration of the right CCA, the external carotid artery, and internal
carotid artery. A 4-0 monofilament nylon suture (27.0–28.0 mm) was advanced from the CCA
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bifurcation until it blocked the origin of the MCA. The contralateral CCA was temporally ligated
for 10 minutes to ensure a consistent blood flow occlusion (including collaterals) to the brain.
Animals were allowed to recover from anesthesia during MCAO. After 60 minutes of transient
MCAO, animals were re-anesthetized with 1–2% isoflurane in nitrous oxide/oxygen (69%/30%)
using a face mask and reperfused by withdrawal of the nylon thread. Animals receiving the sham
operation were anesthetized with 1–2% isoflurane in nitrous oxide/oxygen (69%/30%) via face
mask. A midline incision was made in the neck and the right CCA was isolated. The animals
were then closed and allowed to recover from anesthesia.
4.2.2. MSCs Cell Culture and Co-culture
MSCs (T4835;abm) were maintained with α-MEM (12561056; Gibco) supplemented
with 20% FBS (FBS001; Neuromics), 1% penicillin/streptomycin (15140122; Gibco), 1% nonessential amino acids (11140050; Gibco), 1% GlutaMax-I (35050061; Gibco) in incubator (37°C
humidified, with 5% CO2, 95% air).
Prior to co-culture experiments, MSCs were seeded at 0.5 x 105 cells/insert in cell culture
inserts (353493, Falcon). After OGD, the RPE cells were co-cultured with MSCs by placing the
inserts into the wells of the 6-well plate for 24 hours.
4.2.3. MSCs Transplantation
On the day of transplantation, MSCs were detached using TrypLE (Gibco 12604-021).
Complete media was used to rinse the flask for maximizing cell yield. The MSCs were
centrifuged at 300x g for 10 minutes. After the supernatant was aspirated, the cells were resuspended in normal media. A small volume of cells were set aside for cell count. The cells were
then centrifuged at 300x g for 5 minutes. Once the supernatant was aspirated, the cells were re34

suspended in final concentration of 4x106 cells/500 µL of sterile PBS. The animals were
anesthetized and transplanted intravenously via the jugular vein with MSCs or with PBS only.
4.2.4. Immunohistochemistry
The retinas were embedded in 4% agarose and sectioned with a vibratome at 30 μm
thickness in ice cold PBS. The tissues were incubated in blocking buffer (5% normal goat serum
and 0.1% Tween 20 in PBS) for 3 hours at 4°C. The tissues were then incubated with NeuN
(1:500; ab104225, Abcam) in blocking buffer at 4°C overnight. Thereafter the tissues were
washed three times with PBS followed by incubated with Alexa 488 secondary antibody (1:500)
for 4 hours at 4°C. The tissues were further washed three times with PBS and mounted with antifade mounting medium containing DAPI (H-1500; Vector Laboratories)
4.2.5. RPE Cell Culture
RPE (CRL-4000; ATCC) cells were cultured in DMEM/F-12 (11320033; Gibco)
containing 10% fetal FBS (FBS001; Neuromics) and 0.01 mg/ml hygromycin B (10687010;
Gibco) in incubator (37°C humidified, with 5% CO2, 95% air).
4.2.6. OGD: A Cell Culture Stroke Model
A day prior to the experiment, RPE cells were seeded at 1.5x105 cells/well in 6-well
plate. On the day of experiment, the media of the RPE cells was changed to DPBS; (14040133;
Gibco). The cells were placed in a sealed hypoxia incubator chamber (27310; StemCell
Technologies) containing 95% N2 and 5% CO2) for 3 hours, mimicking the ischemic stroke. We
chose 3 hours because based on our experience with RPE cells, 3 hours OGD provided 50-60%
cell death. After the 3 hours period, fresh media was reintroduced and the cells were incubated in
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normoxia condition (37°C humidified atmosphere containing 5% CO2) for 24 hours, which
simulated the reperfusion in clinical setting.
4.2.7. Mitochondrial Respiration Assay
On the day of experiments, RPE cells were detached from cell culture plates and seeded
to a Seahorse 96-well plate (101085-004; Agilent) coated with Poly-D-lysine (100µg/ml; P7886;
Sigma) at 5.0 x 104 cells/well. The cells were immobilized by centrifugation method. Briefly, the
Seahorse 96-well plate was centrifuged in swing bucket rotator with slow acceleration (4 on a
scale of 9) to a max speed of 450 rpm with 0 brake. Next, the plate orientation was reversed and
centrifuged again to max speed of 650 rpm with 0 brake. To determine cellular OCR, the
Seahorse extracellular flux analyzer XFe96 (102416; Agilent) was used in combination with
sequential injection of various compounds (1 µmol/L oligomycin, 1 µmol/L carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone (FCCP), 0.5 µmol/L Rotenone and Antimycin A). OCR
measurements were performed according to the manufacturer’s protocol.
4.2.8. Mitochondrial Network Analysis
The RPE cells were stained with MitoTracker (500 ηmol/L; M22426; Invitrogen) for 30
minutes in an incubator (37°C humidified, with 5% CO2, 95% air). Next, the cells were carefully
washed 3 times with DPBS, pH 7.4 to remove any excess dye residue. The cells were fixed with
4% PFA at room temp for 30 minutes. Finally, the cells were washed with DPBS and covered
with anti-fade mounting medium containing DAPI (H-1500; Vector Laboratories). Images were
captured using an Olympus FV1200 Spectral Inverted Laser Scanning Confocal Microscope and
analyzed using ImageJ (NIH) with mitochondrial network analysis (MiNA) plugin.
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4.2.9. Cell Viability Assay
The RPE cells were incubated with calcein-AM (1 µmol/L; 4892010K;Trevigen) for 30
minutes in an incubator (37°C humidified, with 5% CO2, 95% air). Bright green fluorescence
was retained within living cells. The number of cells were counted using ImageJ (NIH) and
averaged per field of view (FOV).
4.2.10. Mitochondria Live Cell Imaging
The mitochondria of RPE cells were incubated with either mitochondrial membrane
potential probe JC-1 (2 µg/mL; T3168; Invitrogen) or with MitoTracker (500 ηmol/L; M22426;
Invitrogen) for 30 minutes in an incubator (37°C humidified, with 5% CO2, 95% air). Thereafter,
the cells were carefully washed 3 times with PBS, pH 7.4 to remove any excess dye residue.
Finally, the media was changed to DMEM without phenol red (21063029, Gibco). Live images
were captured at using an Olympus FV1200 Spectral Inverted Laser Scanning Confocal
Microscope.
4.2.11. Immunocytochemistry
The RPE cells were rinsed a 3 times with DPBS and then fixed with 4% PFA for 20
minutes at room temperature. The cells were rinsed again for a 3 times and permeabilized with
0.3% Triton-X (X100; Sigma) for 5 minutes at room temperature. The cells were further rinsed a
3 times and incubated with blocking buffer containing 5% goat serum (50062Z; Invitrogen) at
room temperature for 60 minutes. The cells were incubated with primary antibodies either rabbit
anti Ki67 (1µg/ml; NCL-Ki67P; LeicaBiosystems), DRP1 (70278; Life Technologies), or MFN2
(711803; eBioscience) at 4°C overnight. After rising several times with DPBS, the cells were
incubated with Alexa Fluor 488 goat anti-mouse (Life Technologies) or Alexa Fluor 488 goat
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anti-rabbit for (Life Technologies) 60 minutes at room temperature. The cells were then rinsed
with DPBS and covered with anti-fade mounting medium containing DAPI (H-1500; Vector
Laboratories).
4.3.

Results

4.3.1. MSCs Rescue Against Ganglion Cell Death in MCAO Stroke Model
We investigated the hypothesis that MSCs could rescue against the ganglion cell death
caused by MCAO (Figure 4.1). Twenty-four hours after surgery, stroke animals received either
MSCs or PBS via intravenous transplantation using the jugular vein. ANOVA revealed
significant differences in ganglion cell count between groups (F(3,35)=28.71,p<0.0001).
Interestingly, transplantation of MSCs showed a trend toward a reduction in ganglion cell death
at day 3 and a significant reduction in the ganglion cell loss at day 14 (post-hoc test p>0.05 and
p=0.0026, respectively) compared to respective MCAO groups. There were no significant
differences between MCAO group and MCAO+PBS group at day 3 and day 14 post stroke (posthoc tests p(s)>0.05). Similar to previous experiment, we showed that MCAO caused ganglion
cell loss at day 3 and day 14. Of interest, we demonstrated that intravenous transplantation of
MSCs recued the ganglion cell death at day 14.
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Figure 4.1: Intravenous transplantation of MSCs rescued ganglion cell loss at day 14 post-stroke.
Representative images and quantification of NeuN immunohistochemical staining for ganglion
cells of the retina at day 3 and day 14. There were significant ganglion cell deaths in MCAO
animals compared to sham at day 3 and day 14. MSCs significantly rescued against ganglion cell
death at day 14 compared to the respective control and vehicle. ANOVA with Bonferroni’s posthoc test ***p<0.001. Bar graphs represent mean ± SD (n=6). Scale bar 50 µm. Contra:
Contralateral; Ipsi: Ipsilateral.
4.3.2. MSCs Ameliorate OGD-induced RPE Cells Loss by Promoting Cell Proliferation
We further investigated the observed therapeutic effect of MSCs under in vitro settings
using OGD model (Figure 4.2). Cell viability and cell proliferation were assessed using calcein
and Ki67 staining, respectively. ANOVA revealed significant differences in cell viability
between groups (F(3,20)=45.75,p<0.0001), with OGD-RPE cells showing a significant decrease
in cell viability compared to the control (119±70 and 1068±110, respectively, post-hoc test
p<0.001). In contrast, co-culture with MSCs after OGD rescued the RPE cells’ viability
compared to OGD group (512±327 and 119±70, respectively, post-hoc test p<0.01).
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Additionally, ANOVA revealed significant differences in the Ki67/DAPI intensity ratio between
groups (F(3,181)=47.03,p<0.0001) with OGD-RPE cells displaying a significant reduction in the
intensity ratio compared to the control (2.27±0.73 and 2.83±0.47, respectively, post-hoc test
p<0.01). Co-culture with MSCs after OGD increased the intensity ratio compared to OGD group
(3.63±0.62 and 2.27±0.73, respectively, post-hoc test p<0.001). Interestingly, co-culture with
MSCs with control did not increase the intensity ratio compared to control (2.63±0.55 and
2.83±0.47, respectively, post-hoc test p>0.05). Overall, the results demonstrate that MSCs
prevented cell loss after OGD by promoting cell proliferation.

Figure 4.2: MSCs rescue against RPE cells loss caused by OGD by promoting cell proliferation.
(A) Representative images of immunocytochemical staining of Ki67 (marker for cell
proliferation). OGD produced a significant decrease in Ki-67/DAPI intensity. Co-culture with
MSCs increased Ki-67/DAPI intensity after OGD. (B) Representative images of Calcein AM cell
viability test. OGD induced a significant decrease in cell viability. Co-culture with MSCs
rescued RPE cell death after OGD. (C) Quantification graphs of Ki-67/DAPI intensity and cell
viability. ANOVA with Bonferroni’s post-hoc test **p<0.01;***p<0.001. Bar graphs represent
mean ± SEM. Scale bar 50 µm. OGD: Oxygen glucose deprivation; MSC: Mesenchymal stem
cell.
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4.3.3. MSCs Attenuate RPE Cells’ Mitochondrial Respiration Deficits Caused by OGD
We further evaluated the effect of MSCs on the RPE cells’ mitochondrial respiration after
OGD. RPE cells’ mitochondrial respiration was analyzed using Seahorse XFe96 extracellular
flux analyzer (Figure 4.3). Co-culture with MSCs significantly rescued the overall mitochondrial
respiration across all indices compared to OGD group as revealed by increased basal respiration
(22.1±2.5 and 13.8±2.3, respectively; post-hoc test p<0.0001), increased spare respiratory
capacity (27.4±3.3 and 13.1±3.0, respectively; post-hoc test p<0.0001), and increased ATP
production (18.2±2.0 and 12.5±2.0, respectively; post-hoc test p<0.0001). Interestingly, we
observed also a decreased in proton leak in the OGD group compared to the control or the OGDMSCs (1.4±0.7, 3.9±0.7, and 5.0±0.7, respectively; post-hoc test p’s<0.0001). In summary, these
results revealed that MSCs restored the mitochondrial respiration deficits caused by OGD.
ANOVA analysis is summarized in Table 4.1.

Figure 4.3: MSCs ameliorate RPE cells’ mitochondrial respiration deficits caused by OGD. RPE
cells’ mitochondrial respiration was analyzed using Seahorse XFe96 extracellular flux analyzer.
41

The OCRs were measured at baseline and after sequential injections of compounds (1 µmol/L
oligomycin, 1 µmol/L FCCP, 0.5 µmol/L Rotenone and Antimycin A). Co-culture with MSCs
restored RPE cells’ mitochondrial basal respiration, spare respiratory capacity, proton leak, and
ATP production compared to OGD. Oligo: Oligomycin; FCCP: carbonyl cyanide 4(trifluoromethoxy) phenylhydrazone; Rot/AA: Rotenone and Antimycin A. ANOVA with
Bonferroni’s post-hoc test **p<0.01;***p< 0.001. Bar graphs represent mean ± SEM control
(n=11), OGD (n=12), OGD-MSC (n=12).
Table 4.1: ANOVA analysis of mitochondrial respiration parameters.

Basal Respiration
Spare Respiratory Capacity
ATP production
Proton Leak

ANOVA Analysis
F(2,32)=82.03,p<0.0001
F(2,32)=85.51,p<0.0001
F(2,32)=55.69,p<0.0001
F(2,32)=80.77,p<0.0001

4.3.4. MSCs Restore RPE Cells’ Mitochondrial Networks that were Altered by OGD
We also investigated whether MSCs could reverse the impaired RPE cells’ mitochondrial
network morphology caused by OGD (Figure 4.4). The measured parameters were previously
discussed in section 3.3.2. Compared to OGD group, co-culture with MSCs significantly
increased the total mitochondrial footprint (45.8±14.4 and 38.9±12.3, post-hoc test p<0.0001),
increased individuals of mitochondria (77.9±30.7 and 58.8±20.1, post-hoc test p=0.0046),
increased the number of network (8.89±4.24 and 6.59±2.80, post-hoc test p=0.0180), increased
mean average branches (6.02±2.10 and 4.74±1.27, post-hoc test p=0.002), and decreased
circularity (0.48±0.07 and 0.53±0.07, post-hoc test p=0.0028), but not the average branch length
(0.81±0.09 and 0.79±0.10, post-hoc test p>0.5). Altogether, these results demonstrate that MSCs
rescued the mitochondrial network morphology which was altered by ischemia. ANOVA
analysis is summarized in Table 4.2.
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Figure 4.4: MSCs restore RPE cells’ mitochondrial networks altered by OGD. (A)
Representative images of RPE cells stained with MitoTracker. (B) Analysis and quantification of
RPE cells’ mitochondrial network morphology. Co-culture with MSCs increased RPE cells’
number of mitochondrial networks, number of individual mitochondria, and number of branches
but not average length of the branches compared to OGD. In addition, co-culture with MSCs
decreased the circularity of RPE cells’ mitochondria compared to OGD. ANOVA with
Bonferroni’s post-hoc test *p<0.05;**p<0.01;***p<0.001. Bar graphs represent mean ± SEM
Scale bar 10 µm.
Table 4.2: ANOVA analysis of mitochondrial network parameters.

Footprint
Networks
Individuals
Circularity
Mean Branch Length
Mean Network Branches

ANOVA Analysis
F(3,167)=8.312,p<0.0001
F(3,167)=5.774,p=0.0009
F(3,167)=9.955,p<0.0001
F(3,167)=13.36,p<0.0001
F(3,167)=10.64,p<0.0001
F(3,167)=4.580,p<0.0001
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4.3.5. MSCs Reduce RPE Cells’ Mitochondrial Membrane Depolarization Induced by OGD
and Mitochondrial Transfer as a Potential Mechanism of Action Mediating MSC Therapeutic
Effects
RPE cells’ mitochondrial membrane potential was analyzed using JC-1 staining (Figure
4.5). ANOVA revealed significant differences between groups in the JC-1 red/green intensity
ratio (F(3,119)=13.50,p<0.0001). Bonferroni’s post-hoc tests showed that OGD-RPE cells had
significant decrease in the JC-1 red/green intensity ratio compared to the control RPE cells
(0.94±0.59 and 1.63±0.49, respectively, p< 0.0001). Co-culture with MSCs significantly
increased JC-1 red/green intensity ratio compared to OGD group (1.35±0.51 and 1.63±0.49,
respectively, post-hoc test p<0.005). A decrease in JC-1 red/green intensity ratio indicated OGDRPE cells’ mitochondria were unhealthy with depolarized mitochondrial membrane. Conversely,
co-culture with MSCs increased the JC-1 red/green intensity ratio, thus significantly reducing the
mitochondrial membrane depolarization.
It is worth noting that MSCs’ mitochondria were observed in both OGD-MSC and
control-MSC groups. Confocal imaging revealed co-localization between MSCs’ mitochondria
(blue) and JC-1 (red) indicating the transfer of functional mitochondria from MSCs to RPE cells
(Figure 4.6). Indeed, analysis of co-localization of green/blue and red/blue signals is summarized
in table 4.3. In particular, there is a positive correlation between JC-1 red signal and MSCs’
mitochondria blue signal (Pearson’s coefficient = 0.65 ± 0.08) with M1 & M2 coefficients of
0.57 ± 0.16 and 0.54 ± 0.18, repectively. This mitochondrial transfer phenomenon was
confirmed with immunocytochemical staining as evidenced by deposition of MSCs’
mitochondria within the boundary of RPE cells (Figure 4.7). Furthermore, correlational analysis
revealed that there was a positive correlation between the percentage of cells with transferred
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mitochondria and the cell viability (r= 0.9402, n= 35, p<0.0001 with a R2= 0.8840; Figure 4.8).
In summary, these results indicate that MSCs reduced RPE cells’ mitochondrial membrane
depolarization caused by OGD in part possibly via transfer of MSCs’ functional mitochondria.

Figure 4.5: MSCs reduce RPE cells’ mitochondrial membrane depolarization caused by OGD.
RPE cells’ mitochondrial membrane potential was analyzed using JC-1 staining. Representative
images of JC-1 dye (red and green) and transferred MSC’s mitochondria (blue). Bar graph
represents red/green (healthy/unhealthy) intensity ratio of JC-1 staining. OGD-RPE cells
displayed a significant decrease in the JC-1 red/green intensity ratio compared to the control RPE
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cells. Co-culture with MSCs significantly increased JC-1 red/green intensity ratio compared to
OGD. ANOVA with Bonferroni’s post-hoc test **p<0.01;***p<0.001. Bar graphs represent
mean ± SD. Scale bar 10 µm.

Figure 4.6: MSCs transferred mitochondria to ischemic RPE cells. Confocal imaging revealed
co-localization between MSCs mitochondria (blue) and JC-1 (red, arrows) indicating the transfer
of functional mitochondria from MSCs to RPE cells. Scale bar 10 µm.

46

Table 4.3: Co-localization analysis of JC-1 intensity and MSCs’ mitochondria.

Green & Blue Pearson's Coeff.
M1 Index
M2 Index
Red & Blue Pearson's Coeff.
M1 Index
M2 Index

Control-MSC
(n=36)
0.90 ± 0.02
0.49 ± 0.13
0.70 ± 0.16
0.60 ± 0.07
0.59 ± 0.12
0.60 ± 0.17

OGD-MSC
(n=57)
0.84 ± 0.05
0.53 ± 0.21
0.61 ± 0.17
0.65 ± 0.08
0.57 ± 0.16
0.54 ± 0.18

Figure 4.7: MSCs’ mitochondria were detected in RPE cells after OGD. MSCs’ mitochondria
were separately stained with Mitotracker prior to co-culture with RPE cells. Confocal images of
RPE cells with DAPI (blue), β-tubulin (red), and MSCs’ mitochondria stained with Mitotracker
(green). MSCs’ mitochondria were detected within the boundaries of RPE cells. Scale bar 10
µm.
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Figure 4.8: Correlational analysis between mitochondria transfer and cell viability. There was a
positive correlation between the percentage of cells with transferred mitochondria and number of
viable cells (n=35).
4.3.6. MSCs Repair RPE Cells’ Mitochondrial Dynamics via Mfn2 after OGD but not Drp1
We further investigated the deleterious effect of OGD and therapeutic effect of MSCs on
mitochondrial dynamic proteins Mfn2 and Drp1. Immunocytochemical assay of Mfn2 revealed
that there were significant differences between groups ([F(3,307)=15.65,p<0.0001; Figure 4.9).
OGD significantly reduced the expression of Mfn2 compared to the control (post-hoc test
p<0.0001). Co-culture with MSCs significantly restored the expression of Mfn2 compared to the
OGD-RPE group (post-hoc test p<0.0001). Immunocytochemical assay of Drp1 revealed that
there were significant differences between groups ([F(3,80)=9.747,p<0.0001; Figure 4.10). OGD
significantly increased the expression of Drp1 compared to the control (post-hoc test p<0.05),
but co-culture with MSCs did not significantly restore the expression of Drp1 to normal level
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(post-hoc test p>0.05). These results show that OGD altered the mitochondrial dynamic proteins
Mfn2 and Drp1, while co-culture with MSCs normalized the expression of Mfn2, but not Drp1.

Figure 4.9: MSCs normalize RPE cells’ mitochondrial dynamics via Mfn2 after OGD.
Representative images of Mfn2 expression (left columns), DAPI (middle columns) and merged
(right columns). OGD caused a significant decrease in Mfn2 expression. Co-culture with MSCs
significantly increased the Mfn2 expression compared to OGD. ANOVA with Bonferroni’s posthoc test *p<0.05;**p<0.01;***p<0.001. Bar graphs represent mean ± SD. Scale bar 50 µm.
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Figure 4.10: MSCs did not restore RPE cells’ Drp1 expression level after OGD. Representative
images of Drp1 expression (left columns), DAPI (middle columns) and merged (right columns).
OGD caused a significant increase in Drp1 expression. Co-culture with MSC did not decrease
the Mfn2 expression compared to OGD. ANOVA with Bonferroni’s post-hoc test * p<0.05;
**p<0.01; ***p< 0.001. Bar graphs represent mean ± SD. Scale bar 50 µm.
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4.4.

Conclusion
In the present study, we demonstrated that intravenous transplantation of MSCs

significantly rescued retinal ganglion cell death in MCAO stroke model at day 14. MSCs
promoted cellular proliferation by increasing Ki-67 expression and rescued RPE cell loss in
OGD in vitro stroke model. Of note, that co-culture MSCs with control RPE cells did not
increase Ki-67 expression, suggesting that injured or “help-me” signals might be necessary for
MSCs to exert therapeutic effects. Furthermore, MSCs attenuated the mitochondrial respiration
deficits caused by ischemia and rescued the mitochondrial network morphology. In particular,
co-culture with MSCs increased the overall mitochondrial footprint, increased the number of
mitochondrial networks, and decreased the mitochondrial circularity. These observations indicate
that MSCs returned the mitochondria to healthier state with tubular mitochondria and more
intricate network. In addition, JC-1 staining showed that MSCs rescued the mitochondrial
membrane depolarization caused by OGD. Restoring the mitochondrial membrane potential is
essential for the function of mitochondria. Interestingly, we demonstrated that the mitochondrial
transfer phenomenon occurs between MSCs and RPE cells. Immuncytochemistry and JC-1 live
cell imaging revealed that MSCs transferred healthy mitochondria to injured RPE cells. Indeed
correlational analysis showed that the higher number of RPE cells with transferred mitochondria
correlated with higher cell viability. Additionally, OGD disrupted mitochondrial dynamics
proteins Mfn2 and Drp1 which play important role in regulating mitochondrial fusion and fission
processes, respectively. Co-culture with MSCs after OGD normalized the expression of Mfn2
but did not restore the Drp1 expression level to normal. A preferential restoration of the
mitochondrial fusion over fission dynamics was evident in our data, in that MSCs promoted
mitochondrial fusion which might facilitate the integration of the transferred MSCs’
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mitochondria into RPE cell’s mitochondrial network. Furthermore, this observation seems to
support the mitochondrial network analysis of RPE cells after co-culture with MSCs.
Specifically, compared to OGD group, while there was no significant difference in the average
length of the network branches, there was significant increase on average more branches per
network in co-culture with MSCs group. A possible explanation is that MSCs transferred and
facilitated the integration of mitochondria into the network by promoting mitochondrial fusion.
Taken together, the results demonstrated that MSCs promoted cell survival rescued
mitochondrial dysfunction and shifted the mitochondria to a normalized and functional state (i.e.
tubular mitochondria and intricate network) possibly via transfer of healthy mitochondria.
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Chapter 5: Discussion
Stroke remains one of the leading causes of death and disability in the United States 1.
Recent advances in stroke awareness and treatment protocols have reduced the overall mortality
rate 1. Yet, stroke patients continue to experience a wide range of functional disability with
severe emotional and financial consequences 1. Furthermore, the current limited stroke treatment
options focus in restoring blood flow with narrow therapeutic window targeting the early stage of
stroke pathology 2-5. To date, physical therapy is the only option to mitigate the disabilities
associated with chronic stroke. Moreover, visual impairment is a common disability in stroke
patients, but largely an ignored stroke consequential symptom. Visual impairment affects the
ability for stroke patients to exhibit functional recovery and improved quality of life 10, 11. Retinal
ischemia is a major underlying cause of visual impairment in stroke and it is a shared pathology
with other common ocular vascular diseases such as glaucoma, diabetic retinopathy, and CRAO
20-27

. There are many risk factors associated with both cerebral ischemia and CRAO 27, 28. Due to

the anatomical proximity of the ophthalmic artery and the MCA, ischemic stroke resulting from
MCAO is likely to block blood flow to the ophthalmic artery 47. Therefore, treatment regimens
that address cerebral ischemia and retinal ischemia represent as appealing strategies to ameliorate
visual impairments and improve outcome for stroke patients. The underlying mechanism of
retinal ischemia is not fully understood despite pathological similarities with cerebral ischemia.
In particular, the role of mitochondrial dysfunction in retinal ischemia remains to be elucidated.
Mitochondria not only serve as the powerhouse of the cell but also play important role in
maintaining cellular homeostasis, regulating apoptosis and modulating inflammation 117-123.
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Thus, mitochondrial dysfunction which is a key mediator in cerebral ischemia pathology is likely
a principal pathological trigger for retinal ischemia. Therapies designed in combating
mitochondrial dysfunction as a primary target might be beneficial for retinal ischemia, stroke and
other CNS disorders with retinal ischemia pathology. Since its discovery a few decades ago,
stem cell therapy has been investigated for neurological disorders such as stroke 48-51 and ocular
degenerative diseases such as glaucoma, age-related macular degeneration, and diabetic
retinopathy47, 52-55.However, despite years of scientific advancement and limited clinical trials,
the complicated underlying mechanism of cell-based therapy remains elusive and not fully
understood. This lack of in-depth understanding of mechanistic underpinnings of stem cell
therapy corresponds to the fundamental gap in our knowledge before stem cell therapy can be
widely utilized in large-scale clinical settings. The overarching focus of this work is to advance
the understanding of mitochondrial dysfunction as a major mechanism of cell death in strokeinduced retinal ischemia and explore the therapeutic mechanism of stem cell to restore
mitochondrial function thereby providing the basis for cell-based therapies for retinal ischemia,
stroke and other impaired mitochondria-related CNS disorders.
First, we investigated whether MCAO stroke model induces retinal ischemia and retinal
degeneration. We monitored blood flow to brain and eye at baseline, during MCAO and 5minute after reperfusion utilizing laser Doppler. We observed that the perfusion profile of the
eye differs from the brain at baseline, characterized by a much higher blood flow. It might due to
the higher number of vasculatures in the retina than the brain that are detectable by laser Doppler
244, 245

. Furthermore, the difference in collateral blood vessels between retina and brain may also

contribute to the distinct perfusion profiles. However, under the stroke pathological condition,
we demonstrated that MCAO caused similar patterns of significant reduction in blood flow to
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brain and eye. This reduction in blood flow persisted at 5-minute after reperfusion in the
ipsilateral hemisphere and ipsilateral eye compared to control. Since the perfusion of the eye
mirror similarly to the brain, this opens potential application for stroke responders to quickly
assess the severity of certain type of stroke while transporting patients to facilities with imaging
capabilities. The reduction in blood flow in the eye corresponds to retinal ischemia which was
likely the cause of significant retinal ganglion cell loss and optic nerve degeneration at day 3 and
day 14. Our data extend the ischemic retinal injury time course to 14 days compared to previous
studies which showed the retinal ischemia mirrors the cerebral ischemia up to 3 days post stroke
241, 242, 246

. Similar to cerebral ischemia, time is of the essence and the earlier that retinal ischemia

is detected and treated the better the outcome 247-250. However, despite the lack of collaterals,
retinal cells are generally considered to be more resistant to ischemic insults than the brain 25, 27.
Clinical studies suggest that the effective time window for central retinal artery occlusion with
intravenous tPA administration could be up to 6 – 6.5 hours 251, 252. In animal study, due to the
use of different models and species, there are some inconsistencies regarding therapeutic window
which is summarized in a review 25. As noted above, the anatomical juxtaposition of the
ophthalmic artery to the MCA, which similarly gets occluded resulting in retinal ischemia in the
event of MCAO may contribute to the different reperfusion profiles. Because of the unique
“dosing” of vasculature and collaterals (or lack thereof) in the brain and the retina, the discordant
reperfusion profiles will likely affect the stem cell distribution or mitochondrial transfer in these
tissues. Notwithstanding the subtle differences in blood flow and collaterals between the brain
and the eye, it is still important to diagnose and treat retinal ischemia as early as possible similar
to cerebral ischemia.
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Next, we examined the hypothesis that mitochondrial dysfunction plays a key role in
retinal ischemia pathology using in vitro stroke model. Here, we measured the mitochondrial
respiration using Seahorse extracellular flux analyzer XFe96 and utilized immunocytochemistry
to analyze mitochondrial network morphology between control and OGD RPE cells.
Mitochondrial respiration capacity provides direct insights into the ability of mitochondria to
perform the critical function of generating energy for the cells. Similarly, mitochondrial network
morphology provides understanding to the state of mitochondria. For example, healthy
mitochondria have elongated tubular shape and are capable of forming elaborate networks with
multiple branches 73. In contrast, impaired mitochondria display fragmented and spherical shape
morphology 73. Indeed, our data demonstrated that OGD caused significant deficits to
mitochondrial respiration characterized by routine electron transport chain measurements such as
decreased in ATP production and decreased in spare respiratory capacity (the ability to response
to energy demand). Furthermore, ischemic injured RPE cells contained fewer total mitochondria,
decreased numbered of network, and increased circularity. Interestingly, mitochondria in
impaired cells localized adjacent to the nucleus which might be a cellular defensive mechanism
to protect the DNA. Altogether, these data indicate that mitochondrial dysfunction is closely
associated with stroke pathology.
We investigated the hypothesis that transplantation of MSCs is a potential therapeutic
option for retinal ischemia by ameliorating the mitochondrial dysfunction. In animal study, we
demonstrated that intravenous transplantation of MSCs at day 1 post stroke showed a trend
toward rescue at day 3 and significantly decreased retinal ganglion cell loss at day 14 compared
to control and vehicle-treated animals. This histopathological benefit of MSCs supports the
restorative effects of cell therapy in retinal ischemia. We showed that MSCs ameliorate RPE cell
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loss caused by OGD by promoting proliferation in an in vitro stroke model. The possibility also
exists that MSCs also maintained mitochondrial function in spared cells (e.g., ischemic cells in
the penumbra), which would suggest that MSCs mount both protective and reparative effects 209216

. We further examined the effect of MSCs on mitochondrial function and network

morphology. Co-culture with MSCs rescued against mitochondrial respiration deficits caused by
ischemic injury. Furthermore, MSCs improved the mitochondrial network morphology of OGD
RPE cells. In addition, we assessed the mitochondrial membrane potential using JC-1 dye in
order to further evaluate the overall mitochondrial state. Healthy mitochondria will have a JC-1
red/green ration higher than 1, while unhealthy mitochondria will have a ratio less than 1.
Indeed, the results showed that MSCs attenuated the mitochondrial membrane depolarization
caused by ischemia. Most importantly, we demonstrated that MSCs transferred healthy
mitochondria to injured RPE cells which likely contributed to the observed mitochondrial
functional recovery. A logical question arises if the transferred mitochondria would be able to
integrate with the endogenous mitochondrial network. To this end, we examined the
mitochondrial dynamics via the expression of Mfn2 and Drp1 proteins. Mfn2 and Drp1 are
important proteins responsible for fusion and fission of mitochondria, respectively. Under
normal condition, mitochondrial fusion augments mitochondrial function by sharing substances
and mtDNA across the tubular network; while mitochondrial fission facilitate clearance of
damaged proteins and DNA 158, 160, 161. On the other hand, under pathological condition, the
imbalance between mitochondrial fusion and fission leads to apoptosis 162, 163, 166. The
discrepancy between expression of fusion and fission proteins may be critical for the onset of
fragmented spherical mitochondria morphology observed after ischemia. Our data concur with
previous studies demonstrating that after ischemic insults, there is an upregulation of Drp1 and a
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downregulation of Mfn2 164-166. Interestingly, MSCs significantly restored Mfn2 but not Drp1
expression level. As we briefly discussed in section 4.4, this set of data supports the notion that
MSCs promoted the integration of mitochondria into network via upregulating mitochondrial
fusion. Such normalized fusion dynamics may mediate the restored mitochondrial networks in
cells co-cultured with MSCs which displayed on average more branches compared to non-treated
group.
The novel data presented in this work add to the body of scientific knowledge implicating
the role of mitochondria in stroke pathology and its treatment. However, this dissertation, like
most scientific inquiry has limitations and presents as many questions as answers. The focus of
our study is on the mitochondria’s role in retinal ischemia in ganglion cells since they are
neuronal cells that make connections with the brain. However, we did not investigate other cell
types such as photoreceptors, amacrine cells, and residential immune cells of retina, which are
equally vulnerable to ischemic injury. In addition, in the present study, we did not explore visual
behavior tests to evaluate whether the observed cell loss correlate with visual deficits. Including
visual behavior tests in a future study would further strengthen the significance and clinical
relevance of these findings. While this study focused in mitochondrial dysfunction and proposed
the transfer of mitochondria as a mechanism of MSCs, other mitochondria-relevant organelles
(e.g., endoplasmic reticulum, microvesicles, and exosomes) which may be altered in stroke
pathology and treatment are potential targets that need to be considered in future investigations.
Future studies could focus on the contribution of these mitochondrial components to the
pathologic and treatment outcomes. As previously discussed, the other established mechanisms
mediating stem cell therapy such as by stander effects including secretion of growth factors, antiinflammatory, anti-oxidative, and anti-apoptotic substances, are as equally important as the
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transfer of mitochondria. Future studies could investigate the potential synergestic effects if any
between these stem cell mechanisms of action. The transfer of mitochondria from MSCs to
ischemic retinal cells to amend mitochondrial impairment begs the question of signaling
pathways involved in the release and uptake of mitochondria. In the context of in vivo stroke,
injured cells release “help me signals” which could be used to guide the migration of stem cells
to the target area such as brain or retina 253. Recent literature has offered equally compelling
evidence of other potent mechanisms associated with mitochondrial transfer (e.g. TNTs, EVs,
gap junctions, and cell fusion)122, 227, 228, 235, 237, 238. In the present study, we employed the noncontact co-culture system between MSCs and retinal cells. Hence, in our case, the mitochondrial
transfer occurs likely through extracellular vesicles. This raised certain questions. How do these
vesicles form? What is the minimal and optimal size of these vesicles containing mitochondria?
How far can the released vesicle travel? Are there other molecules in these vesicles that could
contribute to the observed benefits? Addressing these questions will further elucidate the
underlying mechanism. On this note, utilizing rho-like MSCs that do not contain mitochondria,
isolated mitochondria, or changing the pore size of the co-culture membrane are some of the
alternative approaches to answer these questions. Moreever, studies that focus in the profile and
characteristics of the released vesicles are likely to be beneficials for the understanding of these
vesicles. These approaches also delineate the contribution of mitochondrial transfer compared to
other well-know mechanisms of cell therapy. A better understanding of the underlying
mechanism of mitochondrial transfer will also lay the foundation for developing molecules and
compounds which facilitate the transfer as well as strengthen the function of transferred
mitochondria. Optimizing the timing of MSCs transplantation, routes of delivery as well as
dosage would help to maximize the functional benefits of mitochondrial-based therapy.
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Moreover, despite the shortcomings of tPA, it remains standard treatment of care for stroke.
Future studies should investigate the potential therapeutic effects of tPA with and without stem
cells which could yield insightful knowledge in developing effective mitochondrial treatment.
Notwithstanding these limitations, we demonstrated that MCAO and OGD induced retinal
ischemia, associated with mitochondrial dysfunction. Treatment with MSCs rescued against
retinal cell loss, likely through stem cell transfer of healthy mitochondria and subsequent
restoration of mitochondrial function, network morphology, and dynamics.
In summary, we used a combination of in vitro cell culture and in vivo rat models to
examine the role of mitochondria dysfunction in stroke-related retinal ischemia and whether stem
cells could repair the mitochondria and rescue the ischemic retinal cells. Our results
demonstrated that both MCAO and OGD stroke models produced consistent retinal ischemia
accompanied by massive alterations in retinal cells’ mitochondrial respiration, network
morphology, and dynamics and treatment, which were reversed by stem cell treatment. From the
translational standpoint, because stem cell therapy has reached clinical trials for stroke, a better
understanding of its mechanism of action may optimize the safe and effective application of this
treatment for stroke patients. That cell-free, organelle-based approach such as mitochondria
transplantation may suffice as a clinical product for stroke may circumvent many of the logistical
limitations (e.g., immune response) associated with cell therapy. From the basic science
viewpoint, the appreciation of mitochondria as the powerhouse of the cell highlights the role of
this specific organelle in maintaining cell homeostasis and function under normal and
pathological conditions.
This work is built upon the foundation of many experts in the field of stroke and stem cell
therapy in the quest to find a better treatment options for stroke and relevant vascular diseases.
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Through the efforts of leading experts in the field such as my mentor, I am proud and confident
that the work presented here moves us even just by a little closer to a better treatment option for
diseases that affect millions of people worldwide.
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